announcement, page-2

G'day cabe,

yes very good. the tech works. now lets sell it .... i think there might be a scramble for this tech, and check out the last par, if airway clear becomes standard equipment in neonate wards write your own ticket



Premier Bionics Ltd’s wholly-owned subsidiary Pulmosonix Pty Ltd is
pleased to announce the first phase of the PulmoScreen™ project has been successfully completed.
The company is now accelerating the next phase of the project.
The PulmoScreen™ prototype was designed and developed by the Pulmosonix engineering team. A
proof of concept clinical trial was undertaken at the Alfred hospital in Melbourne, in collaboration
with the Department of Allergy, Immunology and Respiratory Medicine. The team at the Alfred was
led by Associate Professor Trevor Williams. The clinical research was performed by Dr. Hoan Tran
together with Pulmosonix team members. The study involved 10 patients.
The results of the trial demonstrated that the device can clearly determine a difference between
emphysematous and normal lungs utilising the properties of sound transmission. The results were
extremely encouraging because they showed positive identification of the diseased lung in all patients.
Commenting on the trial results, Associate Professor Williams said, "We are very pleased with the
results that have been obtained from the prototype of the PulmoScreen device in this study. This is a
completely new approach to measuring the degree of lung damage in emphysematous patients and the
results have already sparked considerable interest among my colleagues practicing respiratory
medicine."
The development of the functional prototype and its validation in a clinical trial was supported by a
Commonwealth Government R&D Start grant. Following the success of this first phase of product
development and validation (all key milestones having being achieved on time and within budget), the
company recently submitted an application for further funding assistance under the Commercial Ready
grant scheme to support the second phase of product development and clinical trials.
The results obtained to date will be submitted to the Thoracic Society of Australia and New Zealand
for the 2006 Annual Scientific meeting in Canberra in March next year and to the American Thoracic
Society for its prestigious annual congress that will be held in the USA in May 2006.
At the same time, Pulmosonix is continuing clinical studies of its AirwayClear™ device. These
studies are focusing on obtaining additional clinical data from neonatal subjects with a view to
establishing efficacy in detecting apnea in very young patients and are a precursor to further
commercial negotiations.